Sign In
Buy ARTL
$0.770
+0.0148 (+1.96%)
At Close: Jul 31, 2026
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
04:05pm, Wednesday, 25'th Mar 2026
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Cal
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
07:31am, Wednesday, 25'th Mar 2026
Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication Three clinical programs, one core molecule, and
Nano-Cap Artelo Biosciences Stock Explodes — Glaucoma Study Collaboration Ignites Rally
03:14pm, Wednesday, 18'th Mar 2026
ART27.13 is a peripherally selective synthetic cannabinoid.
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
10:41am, Wednesday, 18'th Mar 2026
Biotech and healthcare innovators are advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global ac
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study
08:07am, Wednesday, 18'th Mar 2026
BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glau
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
07:41am, Wednesday, 18'th Mar 2026
Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology
Artelo Biosciences Announces Reverse Stock Split
08:00am, Friday, 06'th Mar 2026
Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Large Decrease in Short Interest
04:10am, Sunday, 01'st Mar 2026
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 53,03
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results
08:00am, Tuesday, 24'th Feb 2026
SOLANA BEACH, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid
Artelo Biosciences Stockholders Approve Directors, Say-on-Pay and Auditor at 2025 Annual Meeting
03:03am, Sunday, 01'st Feb 2026
Artelo Biosciences (NASDAQ: ARTL) held its 2025 annual meeting of stockholders virtually on Jan. 30, 2026, led by President and Chief Executive Officer Gregory Gorgas. The meeting included the company
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Large Decrease in Short Interest
03:52am, Wednesday, 14'th Jan 2026
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 82.6% in December
04:47am, Sunday, 28'th Dec 2025
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 185,968 shares, a growth of 82.6% fro
SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid
Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives Consensus Rating of “Hold” from Analysts
03:32am, Monday, 17'th Nov 2025
Shares of Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) have been assigned an average recommendation of "Hold" from the five research firms that are currently covering the stock, MarketBea
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
08:00am, Wednesday, 12'th Nov 2025
SOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop t
